Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Phase IB/II trial of epcoritamab plus ibrutinib in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

RWRina Li WelkieTVTimothy VoorheesLALapo Alinari

Discussion

Loading...

Member takes

Overview

Phase IB/II trial shows combination of epcoritamab and ibrutinib improves response in relapsed B-cell lymphoma, indicating enhanced treatment efficacy.

Key Points

  • Epcoritamab combined with ibrutinib improved the complete response in aggressive B-cell lymphomas.
  • The phase Ib/II trial involves 38 patients undergoing treatment for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
  • Combination therapy utilizes a bispecific antibody approach with ibrutinib aiming to reduce cytokine release syndrome effects.
  • The findings could enhance future treatment strategies for patients with relapsed B-cell lymphoma, addressing common toxicities.

Cite This Study

Welkie et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e32chttps://doi.org/10.1182/blood-2025-8239
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder2025
  2. 2Trial in progress: Phase 2 trial of epcoritamab in combination with rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell lymphoma2025 · 1 citations
  3. 3Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  4. 4Multicenter, randomized Phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy: Trial in progress2025
  5. 5Epcoritamab monotherapy demonstrates promising efficacy in patients with Richter transformation (RT): 2-year follow-up results from arm 2A of the phase 1b/2 EPCORE CLL-1 trial2025